Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

9. Check if this filing amends a previously filed version of this report

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code BUD

16. Specific lobbying issues

FY 2026 Appropriations for Agencies
---Centers for Disease Control and Prevention
---FDA
---Health Resources and Services Administration (HRSA)


FY 2026 Appropriations for Specific Issues
---Antimicrobial Resistance (General)
---Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---Funding for Strategic National Stockpile
---Pandemic Preparedness
---Pediatric Priority Review Voucher
---Reauthorization of PAHPA
---Vaccine Access & Compensation

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Office of Management & Budget (OMB), Natl Economic Council (NEC), Natl Security Council (NSC), Office of the Vice President of the United States

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code CPT

16. Specific lobbying issues

Antitrust Legislation
---General
---Oversight Pharmacy Benefit Managers

Artificial Intelligence (AI)

Bayh-Dole Act/Tech Transfer
---Bayh-Dole Act
---NIST RFI Regarding the Draft Interagency Guidance Framework for Considering the Exercise of March in Rights
---Reasonable Pricing Clause

Compulsory Licensing

Data Privacy
---BIOSECURE Act

Drug Patenting
---H.R.3160/S.1553: PREVAIL Act
---S.43/H.R.6485: Skinny Labels, Big Savings Act
---S.527: Prescription Pricing for the People Act
---S.1041: Affordable Prescriptions for Patients Act
---S.1095: Stop STALLING Act
---S.1096: Preserve Access to Affordable Generics and Biosimilars Act
---S.1097: Interagency Patent Coordination and Improvement Act of 2025
---S.1546/H.R.3152: Patent Eligibility Restoration Act (PERA)
---S.2276: ETHIC Act
---S.2658: Medication Affordability and Patient Integrity Act
---Dept of Commerce Patent Valuation Fee Proposal
---FTC Orange Book Delisting Initiative
---Patent Tax/fees
---PTO Proposed Rules on Terminal Disclaimer Practice
---Prohibiting Adversarial Patents Act (PAPA)

Foreign Drug Data Protection Law
---BIOSECURE Act

Intellectual Property Enforcement
---China

Patent Reform
---H.R.3160/S.1553: PREVAIL Act
---S.1097: Interagency Patent Coordination and Improvement Act
---S.1546/H.R.3152: Patent Eligibility Restoration Act (PERA)
---Prohibiting Adversarial Patents Act (PAPA)

Patenting of Biological Inventions
---S.1546/H.R.3152: Patent Eligibility Restoration Act (PERA)
---Section 101 Modernization

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), Health & Human Services - Dept of (HHS)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code HCR

16. Specific lobbying issues

FY 2026 Appropriations for Agencies
---ASPR
---Centers for Disease Control and Prevention
---FDA
---Health Resources and Services Administration (HRSA)
---HHS Office of Infectious Disease and HIV/AIDS Policy
---National Institutes of Health

FY 2026 Appropriations for Specific Issues
---Alternative Funding Programs
---Antimicrobial Resistance (General)
---Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---CICP
---Creating Hope Reauthorization Act
---Drug Pricing
---Funding for Strategic National Stockpile
---Influenza Planning & Response
---MCM PRV Reauthorization
---Pandemic Preparedness -R&D Funding for Medical Countermeasures
---PPRV
---Prescription Drug User Fee Act (PDUFA) VIII Implementation
---Project Bioshield
---Reauthorization of PAHPA
---Section 317 Immunization Program
---Vaccines and Infectious Diseases
---Vaccine Injury Compensation Program

340B Drug Discount Program
---H.R.5256: 340B ACCESS Act
---H.R.6166: Lowering Drug Costs for American Families Act
---340B Accountability Act
---Executive Order on Access to Affordable Life-Saving Medications
---Program Implementation & Oversight
---PROTECT 340B Act
---SUSTAIN 340B Act

Accelerated Approval

Artificial Intelligence (AI)

Alternative Funding Programs

Biodefense Research, Development and Procurement Issues (Non-Funding)
---BIOSECURE Act
---House GOP RFI on Supply Chain
---MCM PRV Program Reauthorization
---National Defense Authorization Act 2026
---Reasonable Pricing Clauses in BARDA Contracts
---Reauthorization of Pandemic and All-Hazards Preparedness and Advancing (PAHPA)
---State Strategic Stockpile Act
---Synthetic Nucleic Acid Synthesis Screening
---VICP Loopholes
---WHO Pandemic Preparedness Accord

Biosimilars
---Biosimilar Red Tape Elimination Act
---Interchangeability and Pharmacy Substitution
---Preserve Access to Affordable Generics and Biosimilars Act
---Reimbursement

Cell & Gene Therapy
---H.R.1672: Maintaining Investments and New Innovation (MINI) Act

Clinical Trial Data in China

Data Privacy
---BIOSECURE Act
---Clinical Trial Data in China

Drug Evaluation and Review
---FDA Hiring Flexibility
---PDUFA VIII Negotiations
---Promising Pathway Act

Drug Manufacturing, Quality & Distribution
---Advanced Manufacturing
---Compounding Pharmacies
---Contract Manufacturing Ecosystem in the United States
---Drug Shortages
---Executive Order on Advancing Biotechnology and Biomanufacturing Innovation for a Sustainable, Safe, and Secure American Bioeconomy
---Supply Chain Integrity and Traceability

Drug Patenting
---S.527: Prescription Pricing for the People Act
---S.1041: Affordable Prescriptions for Patients Act
---S.1095: Stop STALLING Act
---S.1096: Preserve Access to Affordable Generics and Biosimilars Act
---S.1097: Interagency Patent Coordination and Improvement Act
---S.2658: Medication Affordability and Patient Integrity Act
---A bill to address patent thickets
---Restrictions on Intellectual Property Rights

Drug Pricing
---H.R.1672: Maintaining Investments and New Innovation (MINI) Act
---H.R.6166: Lowering Drug Costs for American Families Act
---S.526: Pharmacy Benefit Manager Transparency Act
---S.527: Prescription Pricing for the People Act
---S.832: Ensuring Pathways to Innovative Cures (EPIC) Act
---S.1095: Stop STALLING Act
---S.1096: Preserve Access to Affordable Generics and Biosimilars Act
---S.1097: Interagency Patent Coordination and Improvement Act
---S.1302: Increasing Transparency in Generic Drug Application
---Access to Innovative Treatments Act
---Biologics Competition Act
---Biosimilar Red Tape Elimination Act
---CMMI Authority
---COVID-19 Pricing-Related Provisions
---DRUG Act
---Ensuring Access to Generic Medications Act
---Ensuring Timely Access to Generics
---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
---Implementation of the Inflation Reduction Act (IRA) of 2022
---Mandating Exclusive Review of Individual Treatments (MERIT) Act
---Medicare Drug Price Negotiation Act
---Medicare Negotiation and Competitive Licensing Act
---Modernizing and Ensuring PBM Accountability (MEPA) Act
---Most Favored Nation Drug Pricing Proposals
---National Coverage Determination
---Patient Cost-Sharing and Implementation
---Strengthening Innovation in Medicare and Medicaid Act

Efforts to expand the Bio Economy & Bio Manufacturing

Foreign Drug Data Protection Laws
---BIOSECURE Act

Generic Drug Entry
---Enhanced Access to Affordable Medicines Act
---Generic Drug Application Review Reforms
---Incentives for Generic Entry

Issues Relating to Medical Research and Animal Testing
---FDA Modernization Act 3.0

Medicaid
---S.526: Pharmacy Benefit Manager Transparency Act of 2025
---Alternative Payment Arrangements for Gene Therapies
---Coverage of Accelerated Approval Products
---Drug Benefit Design
---Medicaid Drug Rebate Program Rule
---The Medicaid VBPs for Patients (MVP) Act
---Pricing and Rebates
---Value-Based Purchasing (VBP) Rule

National Defense
---National Defense Authorization Act of 2026

National Security
---BIOSECURE Act
---Clinical Trial Data in China
---Most Favored Nation Pricing

Opioid Crisis
---SUPPORT Act

Orphan Drug Issues
---H.R.946/S.1862: ORPHAN Cures Act
---H.R.1262/S.932: Mikaela Naylon Give Kids a Chance Act
---S.705: Innovation in Pediatric Drugs Act of 2025
---Finding Orphan-Disease Remedies with Antifungal Research and Development (FORWARD) Act
---Implementation of the Inflation Reduction Act (IRA) of 2022
---Orphan Drug Tax Credit
---Retaining Access and Restoring Exclusivity (RARE) Act

Pandemic Preparedness
---Drug Supply Chain Management
---R&D Funding for Medical Countermeasures
---Supply Chain Issues
---Temporarily Refundable R&D Credit
---WHO Pandemic Preparedness Accord

Precision Medicine Initiative

Rare Pediatric Disease Priority Review
---H.R.1262/S.932 Mikaela Naylon Give Kids a Chance Act

Reimbursement and Coverage of Innovative Products
---H.R.6166: Lowering Drug Costs for American Families Act
---S.864/H.R.6423: HELP Copays Act
---Access to Innovative Treatments
---Administrative Rebate Rule
---CMMI Authority
---Implementation of the Inflation Reduction Act (IRA) of 2022
---Lower Costs, More Transparency Act
---Mandating Exclusive Review of Individual Treatments (MERIT) Act
---Medicare Drug Price Negotiation Act
---Medicare Part B Physician-Administered Products
---Patient Cost-Sharing and Smoothing
---Prescription Drug Price Relief Act
---Protected Classes
---SAFE STEP Act
---Step Therapy
---Support of Patient Premiums and Cost-Sharing Obligations
---Value-Based Purchasing (VBP) Rule

Vaccines and Infectious Diseases
---Access to Innovative Treatments Act
---Adult Immunization
---Let Injured Americans Be Legally Empowered (LIABLE) Act
---Mandating Exclusive Review of Individual Treatments (MERIT) Act
---Maternal Immunization
---MCM Manufacturing & Capacity
---MCM R&D Incentives
---Monoclonal Antibody Coverage and Utilization
---National Coverage Determination
---PASTEUR ACT
---SAFE STEP Act
---Vaccine Access Improvement Act
---Vaccine and Antimicrobial Resistance Product Development and Incentives
---Vaccine Injury Compensation Modernization Act
---Vaccine Injury Compensation Program
---Vaccine Quality Measure
---Vaccine Safety
---Vaccine Safety Net and Vaccine Infrastructure
---Value of Vaccines and Vaccine Confidence

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Commerce - Dept of (DOC), White House Office, Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), Office of Science & Technology Policy (OSTP), Office of the Vice President of the United States

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code HOM

16. Specific lobbying issues

FY 2026 Appropriations for Specific Issues
---Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---Pandemic Preparedness -R&D Funding for Medical Countermeasures

Biodefense Research, Development and Procurement Issues (Non-Funding)
---Bio COMPETES (Draft)
---BIOSECURE Act
---Biosecurity Modernization and Innovation Act of 2025
---Executive Order on Achieving Efficiency Through State and Local Preparedness
---Executive Order on Withdrawing the United States from the World Health Organization
---Gene Editing
---HHS Reorganization
---MCM PRV Program
---National Defense Authorization Act 2026
---Reauthorization of Pandemic and All-Hazards Preparedness and Advancing (PAHPA)
---Risky Research Review Act
---WHO Pandemic Preparedness Accord

Pandemic Preparedness
---Drug Supply Chain Management
---MCM PRV
---Medical Countermeasure Priority Review Voucher Reauthorization
---Supply Chain Issues

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Office of Management & Budget (OMB), Commerce - Dept of (DOC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), Office of Science & Technology Policy (OSTP), Office of the Vice President of the United States

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code MED

16. Specific lobbying issues

FY 2026 Appropriations for Agencies
---ASPR
---BARDA
---Centers for Disease Control and Prevention
---FDA
---Health Resources and Services Administration (HRSA)
---HHS Office of Infectious Disease and HIV/AIDS Policy
---National Institutes of Health

FY 2026 Appropriations for Specific Issues
---Antimicrobial Resistance (General)
---Advanced Research Projects Agency for Health (ARPA-H) Act
---Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---Funding for Medical Countermeasures
---Funding for Strategic National Stockpile
---Implementation of the Inflation Reduction Act (IRA) of 2022
---MCM PRV Reauthorization
---Pandemic Flu
---Reauthorization of PAHPA
---VICP/CICP

Antimicrobial Resistance

Biodefense Research, Development and Procurement Issues
---HHS Reorganization
---MCM PRV Program

CDC Reform

Pandemic Preparedness
---MCM PRV Reauthorization
---R&D Funding for Medical Countermeasures

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code MMM

16. Specific lobbying issues

FY 2026 Appropriations for Specific Issues
---Alternative Funding Programs
---Antimicrobial Resistance (General)
---Drug Pricing
---Pandemic Preparedness - R&D Funding for Medical Countermeasures
---Vaccines and Infectious Diseases

340B Drug Discount Program
---340B Rebate Pilot Program
---Executive Order on Access to Affordable Life-Saving Medications
---Program Implementation & Oversight
---PROTECT 340B Act
---SUSTAIN 340B Act

Accelerated Approval

Antimicrobial Resistance

Artificial Intelligence (AI)

Alternative Funding Programs

Biosimilars
---Biosimilar Copay
---Biosimilars Red Tape Elimination Act
---Reimbursement

Cell & Gene Therapy
---H.R.1672: Maintaining Investments and New Innovation (MINI) Act

Clinical Trial Data in China

Data Privacy
---Bio COMPETES (Draft)

Drug Evaluation and Review
---FDA Hiring Flexibility

Drug Manufacturing, Quality & Distribution
---Advanced Manufacturing
---Compounded Medicines
---Drug Shortages
---Supply Chain Integrity and Traceability

Drug Patenting
---Restrictions on Intellectual Property Rights

Drug Pricing
---H.R.946/S.1862: ORPHAN Cures Act
---H.R.1492: Ensuring Pathways to Innovative Cures (EPIC) Act
---H.R.1672: Maintaining Investments and New Innovation (MINI) Act
---S.526: Pharmacy Benefit Manager Transparency Act
---S.527: Prescription Pricing for the People Act
---CMMI Authority
---Implementation of the Inflation Reduction Act (IRA) of 2022
---Most Favored Nation Pricing
---Patient Cost-Sharing and Implementation
---PBM Reform
---Strengthening Innovation in Medicare and Medicaid Act

Foreign Drug Data Protection Laws

Medicaid
---H.R.6166: Lowering Drug Costs for American Families Act
---S.526: Pharmacy Benefit Manager Transparency Act
---Alternative Payment Arrangements for Gene Therapies
---Average Manufacturer Price Calculations
---Drug Benefit Design
---Medicaid Drug Rebate Program
---Most Favored Nation in Medicaid
---Pricing and Rebates
---Vaccine Access
---Vaccines for Children Program
---Value-Based Purchasing (VBP) Rule

National Defense
---National Defense Authorization Act of 2026
---NSCEB Recommendations

Opioid Crisis
---Non-Opioid Analgesics
---SUPPORT Act

Orphan Drug Issues
---H.R.946/S.1862: ORPHAN Cures Act
---H.R.1262/S.932: Mikaela Naylon Give Kids A Chance Act
---Implementation of the Inflation Reduction Act (IRA) of 2022
---Orphan Drug Tax Credit
---Pediatric Priority Review Voucher Program Reauthorization

Pandemic Preparedness
---Drug Supply Chain Management
---Medical Countermeasure Priority Review Voucher Reauthorization
---Monoclonal Antibody Coverage and Utilization
---Supply Chain Issues
---WHO Pandemic Preparedness Accord

Precision Medicine Initiative

Reimbursement and Coverage of Innovative Products
---S.864/H.R.6423: HELP Copays Act
---Administration Rebate Rule
---CMMI Authority
---Medicare Part B Physician-Administered Products
---Support of Patient Premiums and Cost-Sharing Obligations

Vaccines and Infectious Diseases
---Adult Immunization
---Countermeasures Injury Compensation Program
---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
---Maternal Immunization
---Monoclonal Antibody Coverage and Utilization
---National Coverage Determination
---Vaccine Injury Compensation Program
---Vaccine Safety and Quality
---Vaccine Safety Net and Vaccine Infrastructure
---Value of Vaccines and Vaccine Confidence

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Commerce - Dept of (DOC), Food & Drug Administration (FDA), Office of the Vice President of the United States

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code SMB

16. Specific lobbying issues

Banking Policy Impacting Emerging Companies

Capital Formation Incentives
---Accredited Investor Definition Review Act
---Adjusting the well-known seasoned issuers definition to allow for a larger financing round using
---American Innovation Act
---Convert public float thresholds to soft triggers from hard triggers to avoid surprise expenses by implementing a rolling average window
---Expanding Access to Capital Act
---Helping Startups Continue to Grow Act
---Small Entity Update Act
---To amend the Federal securities laws to specify the periods for which financial statements are required to be provided by an emerging growth company, and for other purposes.
---To amend the Securities Exchange Act of 1934 to specify certain registration statement contents for emerging growth companies, to permit issuers to file draft registration statements with the Securities and Exchange Commission for confidential review, and for other purposes.
---Update Form S-3 holding period from 12 months to six months to reflect Wall Street standards
---Update public float threshold triggers to align with current market conditions

Capital Market Enhancements
---Accredited Investor Definition
---Public Float Threshold Update

Sarbanes Oxley Section 404 (b)
---Small Issuer Exemption

Small Business Innovation Research (SBIR) Program
---Implementation of the SBIR and STTR Extension Act
---Reauthorization of SBIR and STTR

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Small Business Administration (SBA)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code TAX

16. Specific lobbying issues

FY 2026 Appropriations for Specific Issues
---Vaccines and Infectious Diseases
---VICP/CICP

Capital Formation Incentives

Orphan Drug Issues
---H.R.946/S.1862: ORPHAN Cures Act
---H.R.1262/S.932 Mikaela Naylon Give Kids a Chance Act
---Cameron's Law

Pandemic Preparedness

Research & Development Tax Credit Reforms
---H.R.1: One Big Beautiful Bill Act
---Expensing of R&D Expenditures
---Tax Incentives for Contract Manufacturing Ecosystem

Vaccines and Infectious Disease
---Countermeasure Injury Compensation Fund Amendment Act
---Let Injured Americans Be Legally Empowered (LIABLE) Act
---Vaccine Injury Compensation Modernization Act
---Vaccine Access Improvement Act

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code TRD

16. Specific lobbying issues

CFIUS and Foreign Investment

Drug Importation

Drug Pricing
---Most Favored Nation - CMMI Models
---Reference Pricing in Drug Reimbursement

Foreign Agricultural Biotechnology Laws and Regulations
---China Biotechnology Regulations

Foreign Drug Data Protection Laws
---China Biotechnology Regulations
---A bill to prohibit contracting with certain biotechnology providers, and for other purposes.

Intellectual Property International Enforcement
---China

Synthetic Biotech

Tariffs

Trade Relations
---Bilateral Trade Negotiations
---Section 232
---US-China IP Provisions
---Word Health Organization (WHO) - WHO Pandemic Preparedness Accord

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Commerce - Dept of (DOC), Office of Science & Technology Policy (OSTP), Office of the Vice President of the United States

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

Information Update Page - Complete ONLY where registration information has changed.

20. Client new address

21. Client new principal place of business (if different than line 20)

22. New General description of client’s business or activities

LOBBYIST UPDATE

23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client

ISSUE UPDATE

24. General lobbying issue that no longer pertains

AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

Internet Address:

26. Name of each previously reported organization that is no longer affiliated with the registrant or client

FOREIGN ENTITIES

27. Add the following foreign entities:

28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization

CONVICTIONS DISCLOSURE

29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery, extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
No Yes